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LaMuraglia, MD, Michael T. Watkins, MD, Christopher J. Kwolek, MD, and Richard P. Cambria, MD,
Boston, Mass
Objective: Clinical and anatomic factors predictive of a favorable response to renal revascularization performed for renal
function salvage remain poorly defined. To clarify decision making in such patients we reviewed a contemporary
experience of surgical renal artery revascularization (RAR) performed primarily for preservation of renal function.
Methods: Between June 1990 and March 2001 (ensuring 1 year minimum follow-up), 96 patients with renal insufficiency
(serum creatinine [Cr] concentration>1.5 mg/dL) and hypertension underwent RAR for preservation of renal function.
Study end points included early and late renal function response, progression to dialysis dependence, and long-term
survival. Variables potentially associated with these end points were assessed with univariate analysis, Cox regression
analysis, and logistic regression analysis, and survival was assessed with the Kaplan-Meier method.
Results: Perioperative failure of RAR occurred in 3 patients (3%), with perioperative mortality in 4 patients (4.1%); thus
92 patients were available for long-term follow-up (mean, 39 months). Mean patient age was 70  9 years with a mean
baseline Cr of 2.6 mg/dL (range, 1.5-7.8 mg/dL). Operative management consisted of aortorenal bypass in 38% of
patients, extraanatomic bypass in 38% of patients, and endarterectomy in 24% of patients; 32% of patients required
combined aortic revascularization and RAR, and 27% underwent bilateral RAR. At hospital discharge renal function had
improved (20% decrement in Cr) in 41 (43%) patients, including 7 patients who were removed from dialysis; remained
unchanged in 40 (41%) patients; and declined (20% increase in Cr) in 15 (16%) patients. At last follow-up renal function
was either improved or unchanged in 72% of patients. Predictors of a favorable response to RAR at last follow-up
included stable Cr at hospital discharge (odds ratio [OR], 7.1; 95% confidence interval [CI], 2.5-21.8; P  .0004) and
decreased Cr at hospital discharge (OR, 16; 95% CI, 1.6-307.8; P < .0001); bilateral renal artery repair (OR, 3.1; 95%
CI, 0.9-10.6; P  .07) approached clinical significance. Predictors of worsened excretory function at last follow-up
included decline of renal function at hospital discharge (OR, 28.9; 95% CI, 5.0-165.4; P  .0002), intervention to treat
unilateral renal artery stenosis (OR, 3.8; 95% CI, 0.8-16.6; P .05), and level of baseline Cr (OR, 3.0; 95% CI, 1.0-4.0;
P  .04). Progression to dialysis occurred in 16 (17%) patients. Dialysis-free survival at 5 years was 50%, and overall
actuarial survival at 5 years was 59%. Predictors of progression to dialysis during follow-up included treatment of
complete renal artery occlusion (OR, 6.2; 95% CI, 1.3-29.5; P  .02), early failure of RAR (OR, 3.1; 95% CI, 0.7-14.2;
P  .04) and baseline Cr (OR, 2.9; 95% CI, 1.3-6.1; P  .006).
Conclusion: Long-term clinical success in the preservation of renal function, noted in 70% of patients, can be predicted by
the initial response to RAR and by anatomic factors, in particular, bilateral repair. While extreme (mean Cr>3.2 mg/dL)
renal dysfunction generally is predictive of poor long-term outcome, a subset of patients will experience favorable results,
even to the extent of rescue from dialysis. These results may facilitate clinical decision making in the application of RAR
for renal function salvage. (J Vasc Surg 2004;39:322-29.)
Atherosclerotic renovascular disease (ARVD) has been
well-recognized as an important cause of renal dysfunction,
and likely is the cause of dialysis dependence in 15% to 25%
of all patients who subsequently undergo renal replacement
therapy.1,2 For more than 40 years it has been recognized
that renal artery revascularization can lead to improved
control of hypertension and salvage of excretory function.3
However, contemporary clinical decision making in the
application of renal artery revascularization (RAR) for pres-
ervation of excretory function remains problematic, sec-
ondary to the unpredictability of response to intervention.
This variability in response is likely secondary to the wide
spectrum of clinical syndromes seen in renal artery stenosis;
disparity in defining response to intervention, in terms of
preservation of excretory function; and the spectrum of
intrinsic renal pathologic findings often found in ARVD.4,5
While there is no randomized trial designed to evaluate
the value of RAR in patients with ischemic nephropathy,
multiple retrospective reviews and clinical series have in-
spired increased interest in this topic over the last decade.6-9
While natural history studies have revealed the progressive
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nature of ARVD,10,11 no studies to date adequately define
clinical or anatomic factors predictive of successful rescue of
renal function with RAR. Such data are vital to clinical
decision making in patients with ARVD whose associated
coronary and cerebrovascular disease limits longevity and
increases the risks of intervention.12,13 Various therapies,
including angioplasty, stent placement, and surgical revas-
cularization, have been used to treat ARVD; however, little
is known about factors predictive of the success of interven-
tion.
A previous series from our institution indicated that
RAR before major deterioration in renal function can im-
prove long-term results when renal artery reconstruction is
performed to preserve excretory function.7 This cohort
included both patients with baseline renal insufficiency and
patients who underwent RAR to the entire functioning
renal mass regardless of the status of renal function. The
heterogeneous nature of this population added complexity
in determining patient characteristics with predictive value
in clinical decision making. The current series is a retrospec-
tive review of a contemporary patient cohort with ARVD
and renal dysfunction treated with surgical revasculariza-
tion for renal function preservation. Our focus was on the
clinically relevant end points of early and late functional
response to revascularization, dialysis-free survival, and
long-term survival, with the goal of defining factors predic-
tive of a favorable response to RAR.
PATIENTS AND METHODS
Patient population. From June 1990 through March
2001, 291 patients underwent surgical repair of renal artery
disease at Massachusetts General Hospital. Of this popula-
tion, 96 patients were identified with ARVD and ischemic
nephropathy, defined as baseline serum creatinine concen-
tration (Cr) 1.5 mg/dL or greater, meeting the inclusion
criteria as undergoing reconstructive efforts for preserva-
tion of excretory function. Included in this patient cohort
were 7 patients dependent on dialysis before surgery (pre-
dialysis Cr,1.5 mg/dL). The mean age of the cohort was
70  9 years (range, 32-90 years); 49 patients (51%) were
men, and 47 patients (49%) were women. Systemic athero-
sclerotic disease was manifested by those comorbid condi-
tions typically identified in this population (Table I). Before
RAR, evaluation for coronary artery disease (CAD) was
pursued in 61 patients (64%), and included pharmacologic
stress testing or cardiac catheterization. Mean Cr for the
entire patient cohort was 2.6 mg/dL (range, 1.5-7.8 mg/
dL); 30% of the population had baseline Cr 3.0 mg/dL or
greater (Table II), including 7 patients who required dial-
ysis, initiated in all within 3 weeks of RAR, before surgical
intervention. Clinical, demographic, and follow-up data
were obtained from review of original hospital and surgeon
records and from phone updates. Data to ensure minimum
follow-up of at least 12 months were available for 85% of
patients.
Patient evaluation. Renovascular disease was evalu-
ated by cut film, digital subtraction angiography, or mag-
netic resonance angiography.14 Significant renal artery dis-
ease was defined as stenosis of 75% or greater; 22 patients
(23%) had unilateral disease, and 72 patients (75%) had
bilateral disease. Two patients had undergone nephrec-
tomy before evaluation. A solitary functioning kidney was
noted in 34 patients (35%), and in 20 patients (21%) there
was total occlusion of the treated vessel.
Definitions. For clarification in the recording of pre-
operative clinical information, perioperative results and
complications, late renal functional response, and survival,
the following definitions were applied. Baseline serum Cr
concentration was the level recorded closest to the date of
surgery; in patients who were dialysis-dependent at inter-
vention, the pre-dialysis serum Cr concentration was con-
sidered baseline. Patients were considered to have a single
Table I. Clinical demographic features
Variable n %
Age (y)
Mean 69  9
Range 32  90
Median 71
Gender
Male 49 51
Female 47 49
Hypertension* 96 100
Tobacco use 73 76
Diabetes 16 17
Non-IDDM 14 15
IDDM 2 2
Hyperlipidemia 46 48
COPD 49 51
Coronary artery disease† 69 72
Previous myocardial infarct 55 57
History of CHF 39 41
Previous PTA/CABG 30 31
Cerebrovascular disease 51 53
Peripheral vascular disease‡ 48 50
IDDM, Insulin-dependent diabetes mellitus; COPD, chronic obstructive
pulmonary disease; CHF, congestive heart failure; PTA, percutaneous trans-
luminal angioplasty; CABG, coronary artery bypass grafting.
*Systolic blood pressure150 mm Hg or diastolic blood pressure90 mm
Hg.
†History of myocardial infarct, or stress test results consistent with coronary
artery disease or previous percutaneous or surgical intervention to treat
coronary symptoms.
‡Documented history of claudication, rest pain, ischemic gangrene, or
previous percutaneous or surgical intervention to treat lower extremity
vascular insufficiency.
Table II. Excretory functional status at revascularization
Variable n %
Creatinine concentration (mg/dL)
Baseline
Mean 2.6  1.1
Range 1.5–7.8
1.5–1.9 32 33
2.0–2.9 36 37
3.0 28 30
Dialysis dependence (preoperative) 7 7
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functioning kidney if any of the following criteria regarding
the contralateral kidney were met: surgically or congenitally
absent kidney, no visible nephrogram at contrast-enhanced
arteriography, and no visible nephrogram at gadolinium-
enhanced magnetic resonance angiography.
Regarding patient comorbid conditions, the following
definitions were applied. The presence of CAD was defined
as a history of myocardial infarct, stress test findings consis-
tent with CAD, or previous percutaneous or surgical inter-
vention to treat coronary symptoms. A history of conges-
tive heart failure was defined as current or previous
hospitalization for that disease. Cerebrovascular disease was
considered present if a history of previous stroke, transient
ischemic attack, transient monocular blindness, or previous
carotid endarterectomy was elicited. Peripheral vascular
disease was considered present in all patients with a docu-
mented history of claudication, rest pain, or ischemic gan-
grene, or who had undergone a previous intervention,
percutaneous or surgical, to treat lower extremity vascular
insufficiency. All patients with identified elevated choles-
terol or lipid concentrations, and those receiving medical
therapy for control of cholesterol or lipids were defined as
having hyperlipidemia.
Perioperative death was defined as death within 30 days
of surgery or occurring during hospitalization for RAR.
Major cardiac complications included all myocardial infarc-
tions documented by serial cardiac enzyme determinations
or significant electrocardiographic findings or events that
necessitated transfer to an intensive care unit. Major pul-
monary events included radiographically confirmed pneu-
monia and all primary respiratory events that led to transfer
to an intensive care unit. Early renal function response to
revascularization was based on serum Cr concentration on
postoperative day 7 or the day of hospital discharge if
hospitalization was longer than 7 days. Late renal function
response was based on serum Cr concentration at last
follow-up. For purposes of assessing the early and late renal
function response to revascularization, the following defi-
nitions were applied. Improvement in renal function re-
quired a 20% or greater reduction in serum Cr concentra-
tion; renal function was considered worsened if an increase
of 20% or greater in serum Cr concentration was identified.
All patients with lesser degrees of change in serum Cr
concentration after reconstruction were considered to have
unchanged renal function.
Variables assessed for association with primary end
points included gender, hypertension, preoperative dialysis,
tobacco use, insulin-dependent diabetes mellitus, non–
insulin-dependent diabetes mellitus, hyperlipidemia,
chronic obstructive pulmonary disease, CAD, previous car-
diac intervention, history of myocardial infarction, history
of congestive heart failure, cerebrovascular disease, periph-
eral vascular disease, occluded renal artery on the affected
side, unilateral renal artery stenosis, solitary functioning
kidney, bilateral renal artery stenosis, severe aortoiliac oc-
clusive disease, aortic aneurysm disease, unilateral RAR,
bilateral RAR, nephrectomy, and failure of RAR. End
points assessed included postoperative renal function, late
renal function, dialysis during follow-up, dialysis-free sur-
vival, and actuarial survival.
Statistical methods and analysis. Univariate analysis
of dichotomous variables predictive of study end points
were tested with the Fisher exact test. Odds ratios (OR) for
2 2 tables are conditional maximum likelihood estimates.
Comparisons of continuous predictors between two groups
were tested with the Mann-Whitney test. Multivariate
models for dichotomous outcomes were constructed with
stepwise logistic regression (PROC LOGIC). Univariate
and multivariate models for time to death and time to
dialysis were constructed with proportional hazards regres-
sion (Cox models) and stepwise proportional logistic haz-
Fig 1. Operative management of renovascular disease. One hundred four renal artery revascularization procedures
were performed in 96 patients. Eight patients underwent staged bilateral procedures. Eleven patients underwent staged
or concomitant contralateral nephrectomy.
JOURNAL OF VASCULAR SURGERY
February 2004324 Marone et al
ards regression. R and SAS software were used for statistical
computations (SAS Institute, Cary, NC).
RESULTS
Operative management. One hundred four RAR
procedures were performed in 96 patients, with 8 patients
undergoing staged bilateral revascularization (Fig 1). Pre-
sentation was related to renovascular disease in 61 patients
(64%), whereas the other 35 patients (36%) were referred
initially for repair of either aneurysm disease or aortoiliac
occlusive disease. Bilateral reconstruction was performed in
26 patients, and 70 patients underwent unilateral repair,
including 34 patients with a solitary functioning kidney.
Combined aortic reconstruction was performed in 31 pa-
tients, because of aortoiliac occlusive disease in 9 patients
and significant aneurysm disease in 22 patients. Patency of
all revascularizations was confirmed with intraoperative
Doppler interrogation. Eleven patients underwent staged
or concomitant contralateral nephrectomy secondary to
severe hypertension refractory to medical management.
Morbidity and mortality. There were four (4.1%)
perioperative deaths; three of these occurred during simul-
taneous renal artery and aortic repair. The remainder of the
perioperative morbidity and mortality results are summa-
rized in Table III. No specific clinical or anatomic variables,
including age, diabetes, CAD, history of congestive heart
failure, peripheral vascular disease, cerebrovascular disease,
chronic obstructive pulmonary disease, baseline Cr concen-
tration, hyperlipidemia, bilateral RAR, RAR in the setting
of a reconstituted patent distal renal artery, or concomitant
aortic reconstruction, were significantly associated with
perioperative mortality. With Kaplan-Meier estimates, ac-
tuarial survival at 5 years was 59% (Fig 2). During long-
term follow-up 25 patients died. Six deaths (24%) were
secondary to myocardial infarction, 6 (24%) were from
cerebrovascular events, 3 (12%) were from cancer, 1 (4%)
was secondary to mesenteric ischemia, and the remainder
(36%) were from unknown causes. Cox regression multi-
variate predictors of decreased time to death are presented
in Table IV (online only).
Early functional results. Postoperative improvement
in renal function was identified in 42% of patients; 41%
exhibited unchanged renal function; and 17% experienced
worsening of renal function. Logistic regression analysis
revealed that local complication at operative intervention,
such as postoperative hemorrhage requiring repeat explo-
ration or graft thrombosis, was significantly associated with
an increase in postoperative Cr concentration (OR, 50; 95%
confidence interval [CI], 3.4-747.0; P  .005). Male gen-
der (OR, 3.8; 95% CI, 0.8-17.1; P  .08) showed a trend
toward significance as a predictor of worsened postopera-
tive renal excretory function. All seven patients who re-
quired initiation of dialysis before revascularization were
rescued from dialysis before hospital discharge. Four other
patients had persistent progressive excretory dysfunction,
and required renal replacement therapy within 30 days of
RAR.
Late functional results. In the assessment of long-
term outcome, operative survivors with a minimum of 12
months of follow-up data were considered (85% of the
original cohort). Mean follow-up for this group was 46
months (median, 38.5 months; range, 13-141 months).
Of the surgical survivors, at last follow-up 33% had
improved renal function, 39% had unchanged renal func-
tion, and 28% had worsened renal function. Thus 72% of
the cohort had improved or unchanged Cr concentration at
long-term follow-up. Significant univariate predictors of
long-term improved renal function are presented in Table
V. Logistic regression analysis revealed that favorable early
response to renal artery revascularization (OR, 16.0; 95%
CI, 1.6-307.8; P  .0001) and initiation of dialysis before
intervention (OR, 22.3; 95% CI, 1.6-307.8; P  .02) are
positive predictors of long-term improvement in renal
function. Clearly, initiation of dialysis before intervention
reflects patient selection.
In addition, bilateral RAR approached significance as a
multivariate predictor of long-term improved excretory
Table III. Perioperative morbidity and mortality
Factor n %
Perioperative death 4 4
Myocardial infarction 4 4
Perioperative hemorrhage 1 1
Stroke 4 4
Nonfatal cardiac arrhythmia 2 2
Pneumonia 5 5
Infectious colitis 1 1
Sepsis 1 1
Urinary tract infection 5 5
Wound infection 4 4
Acute graft thrombosis 3 3
Perioperative renal failure
requiring dialysis
4 4
Fig 2. Kaplan-Meier survival curves.
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 2 Marone et al 325
function (OR, 3.1; 95% CI, 0.9-10.5; P  .07). Un-
changed postoperative Cr concentration is a multivariate
predictor of long-term unchanged renal function (OR, 7.1;
95% CI, 2.5-21.8; P .0004). Postoperative worsened Cr
concentration (OR, 28.9; 95% CI, 5.0-165.4; P  .0002)
and baseline Cr concentration (OR, 3.0; 95% CI, 1.0-4.0; P
 .04) were multivariate predictors of worsened long-term
renal function. Finally, male gender is an inverse multivar-
iate (OR, 0.4; 95% CI, 0.1-1.3; P  .027) predictor of
long-term improvement in renal function. All seven pa-
tients who required initiation of dialysis before intervention
were rescued from dialysis during long-term follow-up
(mean, 35.9 months for this subgroup).
Dialysis during follow-up. Dialysis was instituted in
16 patients during follow-up, at a mean of 17 months
(median, 13 months; range, 0-50 months), revealing a 17%
crude rate of progression to end-stage renal disease
(ESRD). Dialysis-free survival in the patient cohort at 5
years was 50% (Fig 3). Univariate predictors of progression
to dialysis during follow-up included baseline Cr concen-
tratin greater than 3.2 mg/dL (P  .0007), revasculariza-
tion of an occluded renal artery (P  .004), and early local
vascular complications (P .03). Multivariate predictors of
progression to dialysis dependence during follow-up are
presented in Table VI. Acute failure of renal artery revascu-
larization was identified as the cause of progressive renal
dysfunction in three patients, and was noted to be a signif-
icant independent predictor of progression to dialysis (OR,
3.1; 95% CI, 0.7-14.2; P .04). Decreased time to dialysis
was assessed with stepwise proportional regression analysis
(Fig 3). Variables associated with decreased time to dialysis
are presented in Table VII (online only). Of note, postop-
erative improvement in renal function was inversely associ-
ated (hazard ratio, 0.24; 95% CI, 0.007-0.085; P  .013)
with decreased time to dialysis, and no patients with post-
operative improved renal function subsequently became
dialysis-dependent during follow-up. Mean follow-up in
this subgroup was 53 months (median, 57 months; range,
3-113 months), with a crude death rate of 50% at 46
months. Only two deaths were attributed to complications
of renal failure.
DISCUSSION
The prevalence of renovascular disease, an important
cause of ESRD, has been reported to be 7% in adults older
than 65 years.15 In patients with ESRD secondary to
ARVD mortality is as high as 50% within 2 years of initiat-
ing dialysis,2 and according to the United States Renal Data
System the number of patients undergoing treatment for
ESRD in the United States has more than doubled over the
last decade.16 Consequent to this dismal natural history
data, and the equivocal results of RAR when applied solely
to cure hypertension, a paradigm shift has occurred, and a
more aggressive posture toward intervention for preserva-
tion of renal function has been justified.8,17,18 However,
prediction of the renal function response to RAR has been
problematic. Finally, to adequately assess the functional
effect of RAR to treat ARVD, clinically relevant end points
such as dialysis-free survival and 5-year survival need to be
assessed with sufficient follow-up. For example, the term
“stable” renal function (after RAR) has meaning only if the
follow-up duration is sufficient and the comparative natural
history of untreated ARVD is known.
Survival without intervention in patients with ARVD
and ESRD is dismal. Mallioux et al2 reported median
survival of 27 months and 5-year survival as low as 10% in
patients in whom ARVD progresses to ESRD. Similar to
the results reported by Conlon et al,12 Baboolac et al19
noted a crude mortality rate of 40% in patients with bilateral
ARVD followed up without revascularization for a median
of 52 months. In the current report the “cost” of interven-
tion in the form of perioperative mortality was 4.1%, which
compares favorably with the combined series mortality
reported by Rimmer and Gennari20 (6% surgical, 5% per-
cutaneous) and by Cherr et al8 (4.6%). Complications of
systemic atherosclerosis (CAD, cerebrovascular disease)
continue to be the principal cause of perioperative and late
mortality, despite an aggressive preoperative screening pro-
gram. Five-year survival estimated with the Kaplan-Meier
method is 59%, and represents an improvement from our
previous report7 and the natural history data noted above.
Cherr et al8 reported a 69% estimated 5-year survival rate
after RAR, and noted that those patients who experienced
progressive deterioration of renal function, requiring renal
replacement therapy, had a median survival of 18 months,
implying that improved renal function conferred a survival
advantage during follow-up. Our data agree with these
results, because those patients who experienced worsened
excretory function as a consequence of RAR for ARVD had
a 13-fold increased risk for late mortality.
The clinical syndrome of “ischemic nephropathy,” de-
scribed by Dean et al,20 denotes the presence of significant
renal artery stenosis associated with excretory dysfunc-
Fig 3. Dialysis-free survival.
JOURNAL OF VASCULAR SURGERY
February 2004326 Marone et al
tion.20 Various means of measuring excretory function
have been applied in the reporting of results of RAR (Cr
concentration, estimated glomerular filtration rate), mak-
ing comparison of results among reports difficult. In this
report measurement of Cr concentration was applied to
facilitate comparison with other series. We admit this mode
of assessment is limited in the postoperative period (per-
haps estimated glomerular filtration rate is more accurate),
secondary to muscle mass turnover, changes in metabolism,
and fluid shifts.21 More accurate assessment of real-time
glomerular filtration rate with nuclear medicine techniques
may lend greater insight into the early response to revascu-
larization, and deserves study.22 Given the limitations of
this measurement, our perioperative results with respect to
renal function are consistent with those reported elsewhere
for both surgical and percutaneous intervention.6,23,24 The
significance of this early response can only be assessed with
long-term follow-up, assessing influence on the clinically
relevant end points of late functional response, dialysis-free
survival, and mortality, as reported herein.
Seventy-two percent of patients experienced improved
or unchanged excretory function during long-term fol-
low-up (38.5 months). These results mirror those reported
by our group previously,7 as well as those reported in the
literature.6,8,9,23 While the issue of long-term graft patency
was not addressed in this series, the topic has previously
been addressed, with reported recurrent stenosis or throm-
bosis rates of 4% to 5%.8,25,26 Of note, a significant number
of patients in our series had a combination of clinical and
anatomic factors (eg, RAR of a single functioning kidney),
such that clinical follow-up was often sufficient to assess
anatomic patency of the RAR. Of considerable interest,
improved early excretory function was significantly associ-
ated with improved late functional results, a finding previ-
ously reported by our group and by others.7,8 The finding
that late functional results are reflected in early success of
RAR have led some authors to suggest that percutaneous
intervention, performed with a reported initial technical
success rate approaching 100% and with early functional
results equivalent to those of surgical RAR, should be
first-line therapy when considering intervention for preser-
vation of excretory function.24 To date there are no reliable
data comparing surgical RAR with endovascular renal ar-
tery intervention, and no reports document long-term
functional results of percutaneous intervention. However,
mid-term results reported by Watson et al,24 in patients
with mean Cr concentration of 1.5 mg/dL, noted that 72%
of patients had improved excretory function after percuta-
neous stenting with a mean follow-up of 20 months.24 In
addition, assisted primary patency rates as high as 100% at 5
years have been reported.27-29 Secondary to these excellent
technical results and the minimally invasive nature of the
procedure, percutaneous endovascular therapy is certain to
assume importance, if not the dominant role, in treatment
of ARVD.
Bilateral renal artery stenosis and renal artery occlusion
are anatomic factors that offer insight into long-term func-
tional results of revascularization. Chabova et al30 identi-
fied bilateral disease as predictive of progressive excretory
dysfunction and progression to ESRD. The benefit of
comprehensive reconstruction has been previously re-
ported, and it is intuitive that rescue of maximal renal
parenchyma should afford the greatest opportunity for
functional salvage.31-33 Comprehensive revascularization
has been our strategy in 72% of patients undergoing either
bilateral renal artery reconstruction or revascularization of a
solitary functioning kidney. Improvement in excretory
function was noted in those patients who underwent bilat-
eral RAR, with a trend toward improved dialysis-free sur-
vival. Conversely, those patients with an occluded renal
artery before revascularization had significantly diminished
dialysis-free survival, suggesting irretrievable renal paren-
chymal injury. This finding reflects the continued judgment
problem of when to revascularize a diminutive kidney sub-
tended by arteries with total proximal occlusion. It has been
our practice to attempt revascularization in such patients
who have reconstitution of a patent distal renal artery. The
lack of significant clinical benefit may be a result of previous
nephrosclerosis or atheroembolic phenomena, as suggested
by Dean et al.20 Alternatively, this may reflect that approx-
imately half of the patients included in this study were
evaluated without the supportive functional information
provided by gadolinium-enhanced renography, which we
believe can be helpful in assessment of renal parenchyma
status.34
The progressive nature of ARVD has been well docu-
mented; however, the clinical correlates of such anatomic
Table V. Univariate predictors of improved long-term
renal function
Variable
Odds
ratio
95%
Confidence
interval P
Preoperative dialysis 15.74 1.77–755.30 .003
Postoperative improved
Cr
12.10 3.96–43.0 .0001
Male gender* 0.35 0.12–0.92 .027
Postoperative worsened
Cr*
0.12 0.003–0.85 .018
Occluded renal artery* 0.24 0.04–1.31 .02
Cr, Creatinine concentration.
*Inverse predictor.
Table VI. Multivariate predictors of dialysis dependence
during follow-up
Variable
Odds
ratio
95% Confidence
interval P
Occluded renal artery 4.63 1.03–20.73 .02
Baseline Cr* 1.81 1.15–2.85 .011
Improved postoperative Cr.† 0.87 0.01–0.61 .01
Cr, Creatinine concentration.
*For each 1 mg/dL increase in serum Cr 1.5 mg/dL there is a 1.8-fold
increase in progression to dialysis during follow-up.
†Inverse predictor.
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progression are elusive, given the variables of unilateral
versus bilateral disease and the status of the renal parenchy-
ma.35,36 Baboolac et al19 reported 51 patients with bilateral
ARVD (90% ipsilateral, 50% contralateral) managed
without RAR and followed up for a median of 52 months.
With product limit estimates, this group noted progression
to dialysis dependence in 30% of patients at 5 years. With
the Kaplan- Meier method, dialysis-free survival was 50% at
5 years in the current series. The crude rate of progression
to dialysis in our patients was 17%, with mean follow-up of
53 months. Only 4 patients (4%) were dialysis-dependent
within 1 month of RAR; three of these patients had acute
graft thrombosis. Similar results have been reported by
Cherr et al8 in 84 patients who required dialysis during
follow-up (crude rate, 17%); 10 of these patients had graft
failure at duplex surveillance. We note herein two impor-
tant predictors of long-term results: early functional im-
provement after RAR was associated with improved dialy-
sis-free survival, and baseline Cr concentration is predictive
of progression to dialysis during follow-up. For each milli-
gram per deciliter increase in Cr concentration a 1.8-fold
risk for progression to dialysis during follow-up was iden-
tified. This finding creates a judgment paradox, because it is
the subgroup of patients with extreme dysfunction who
represent both the triumphs and dismal failures of RAR for
ARVD. Indeed, seven patients in the present series were
removed from dialysis; however, these patients all experi-
enced acute (3-week course) progression to ESRD asso-
ciated with either hypertensive crisis (three patients) or
acute pulmonary edema (two patients). Patients who fit this
particular clinical scenario have been noted previously by
our group, as well as by others, to respond favorably to
revascularization.7,37
In conclusion, surgical revascularization in the setting
of ischemic nephropathy can offer significant benefit in
long-term excretory function, and such benefit translates to
increased dialysis-free survival. Early functional results after
RAR are predictive of the long-term functional result,
including dialysis-free survival. Increased attention will be
given to percutaneous methods of revascularization, given
the reported equivalent short-term anatomic and func-
tional results reported with endovascular therapy. While
not addressed in this report, comparative anatomic and late
functional results of surgical and endovascular therapy of
ARVD need further study. We currently apply both meth-
ods, in accordance with individual patient anatomic and
comorbidity considerations. The present study was under-
taken to aid clinical decision making when considering
RAR for functional preservation in ARVD. While the data
assist in such judgments, they are hardly definitive, and
emphasize the need for prospective study of the spectrum
of clinical and anatomic variables that might be associated
with preservation of renal function with both surgical and
percutaneous RAR.
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DISCUSSION
Dr Kimberley J. Hansen (Winston-Salem, NC). Luke, that
was an excellent presentation of an important paper. We share your
interest in predictors of renal function response after intervention,
and we share many of your observations. We’ve also observed some
differences.
For us, the early function response varies with the severity of
hypertension. The worse the diastolic and systolic pressure, the
better the functional response. It also varies directly with the extent
and severity of disease. The worse the stenosis, including occlu-
sion, submitted to bilateral repair, the better the response.
Also, the severity of renal insufficiency at the moment of
intervention varies directly with the portion improved, that is, if
you reach that severe insufficiency through rapid deterioration of
renal function. If you have all three of these features, 70% of our
patients have early incremental increase in their renal function.
So my question is, in your analysis, did you consider systolic and
diastolic blood pressures as continuous variables of predictors? And
other than those seven dialysis-dependent patients, did you have any
rates of change in renal function leading up to your intervention?
I think the most important similarity in our data is that
improvements in renal function appear to convey dialysis-free
survival. In our patients, those who have improved function at 3
weeks have significant and independent increase in survival. That
effect is observable out to 8 years after operative intervention.
Those patients unchanged, however, appear to behave as
though they’ve worsened. They do not demonstrate improved
survival. That’s led us to conclude that those patients who are
improved demonstrate a good surrogate measure for outcome, but
the patients unchanged are not stabilized and not preserved; in
fact, they’re probably not helped. Your data would seem to suggest
that perhaps the unchanged patients are helped. Have you looked
at the unchanged group, taking into consideration interaction with
preoperative serum creatinine?
And last, the obvious question: Has your early experience with
percutaneous catheter-based intervention demonstrated the same
associations that you’ve observed with surgery?
Dr Luke K. Marone. Let me address the last question first.
Regarding our early experience with catheter-based intervention,
we have not looked at or identified the results thus far in those
patients. I will make a comment, though, that percutaneous or
endovascular-based intervention is starting to play a greater role in
our treatment of these patients.
The next question, regarding hypertension and rate of excretory
function decline. We did not consider hypertension as a continuous
variable in this study. It was simply used as a threshold variable. We did
not analyze the rates of change in excretory function leading up to
intervention, other than in those seven patients who were dialysis-
dependent at the time of revascularization.
I believe your question was regarding patients who had un-
changed function. In our analysis, patients who had improved
function in the early postoperative period had improved dialysis-
free survival and improved late functional results, which would
seem to go together. The patients who had unchanged renal
function in the early postoperative period had unchanged renal
function in long-term follow-up, and did not exhibit a significant
improvement in dialysis-free survival. So I think that on that point
our results would agree.
Dr John W. Hallett (Bangor, Me). This is an important
paper, and certainly encourages us to operate on some of these
patients. But the problem comes in selecting patients for this
procedure, because mortality and morbidity can be so high. Do
you have an algorithm that you use as you look at the patients,
related to whether you have to replace the aorta, other medical
comorbidities, etc, that helps you decide whether you’re going to
operate or do an endovascular therapy?
Dr Marone. I think currently we take the entire patient into
consideration, meaning that we do look at all the medical comor-
bidities, make sure that their coronary artery disease has been
stratified and worked up, and appropriately intervene before we
decide to pursue any surgical intervention.
As I said earlier, the majority of our recent patients are actually
coming to percutaneous intervention. Many recent reviews in the
literature suggest a much lower peri-interventional morbidity rate
than surgical intervention, with nearly equivalent results from the
standpoint of excretory function. No long-term data currently
exist regarding these techniques; however, our results suggest that
initial improved function is a surrogate marker for long-term
dialysis-free survival.
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